Glucagon-like peptide-1 receptor agonists, commonly called GLP-1 medications, have transformed the medical management of obesity and type 2 diabetes. Medications such as semaglutide and liraglutide—and dual GIP/GLP-1 receptor agonists such as tirzepatide—can substantially reduce appetite, improve glycemic control, and support clinically meaningful weight loss.
However, these medications also change how much people eat, which foods they tolerate, and sometimes what they prefer to eat. Research suggests that energy intake may decline by approximately 16%–39% during GLP-1 therapy. When people are eating considerably less, nutrition cannot remain an afterthought. Every meal must work harder to provide adequate protein, vitamins, minerals, fiber, essential fats, and fluids. The central question of the GLP-1 era is therefore no longer simply, “How much weight was lost?” It is also, “What kind of weight was lost, and was nutritional and metabolic health protected along the way?”
Appetite Suppression Is Not the Same as Nutritional Adequacy
GLP-1-based medications promote satiety, reduce hunger, influence food cravings, and slow gastric emptying. These effects can make it easier to maintain an energy deficit, but a smaller food intake also leaves less room for foods that provide little nutritional value. Someone consuming only a fraction of their previous food volume may struggle to obtain sufficient:
- Protein
- Fiber
- Iron
- Calcium
- Vitamin D
- Vitamin B12 and other B vitamins
- Essential fatty acids
- Potassium and magnesium
A 2025 retrospective observational study of adults using GLP-1 receptor agonists found that documented nutritional deficiencies increased from 12.7% within six months of treatment initiation to 22.4% within 12 months. Vitamin D deficiency was the most frequently recorded deficiency. These results do not prove that GLP-1 medications directly cause nutrient deficiencies, particularly because obesity and type 2 diabetes can independently influence nutritional status. They do, however, reinforce the need for proactive assessment and monitoring. In the GLP-1 era, nutritional planning must shift from simply reducing calories to maximizing the nutritional return of each meal.
Protein and the Quality of Weight Loss
Weight loss generally involves reductions in both fat mass and lean tissue. The goal is not necessarily to prevent every change in lean mass, but to minimize unnecessary losses of skeletal muscle, strength, and physical function.
In an exploratory body-composition substudy of the STEP 1 trial, participants receiving semaglutide 2.4 mg experienced substantial reductions in total and visceral fat. Total lean body mass also decreased, although lean mass represented a larger percentage of body weight after treatment. Because lean mass measurements include water, organs, and other nonfat tissues, not only skeletal muscle, these findings should not be interpreted as a direct measure of muscle loss. Nevertheless, they highlight why body composition and physical function deserve attention during substantial weight reduction.
A 2025 joint clinical advisory from the American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association, and The Obesity Society proposed an absolute protein target of approximately 80–120 grams per day as one practical approach for many adults receiving GLP-1 therapy. This is a general range rather than a universal prescription. Protein requirements should be individualized according to body size, age, activity level, kidney function, health status, total energy intake, and treatment goals.
Practical strategies may include:
- Including a meaningful source of protein at each meal
- Eating the protein-containing portion of the meal first when early fullness is a concern
- Dividing protein across several smaller meals rather than consuming one large serving
- Choosing eggs, fish, poultry, Greek yogurt, cottage cheese, lean meat, tofu, tempeh, beans, lentils, or other tolerated sources
- Using a nutritionally appropriate protein shake when whole-food intake is temporarily inadequate
Protein alone is not enough. Resistance exercise provides the physiological stimulus that tells the body to retain and use muscle tissue. A protein-rich diet combined with individualized resistance training is therefore more protective than simply adding protein to an otherwise inactive routine.
Nutrient Density: Making Every Bite Count
When appetite and portion size decline, the order and composition of food become increasingly important. Filling up on sweets, refined snack foods, or heavily processed “diet” products may leave little capacity for essential nutrients.
A nutrient-dense dietary pattern emphasizes foods that provide substantial nutrition relative to their energy content, including:
- Vegetables and fruit
- Beans, peas, and lentils
- Whole grains, when tolerated
- Nuts and seeds
- Fish and seafood
- Eggs
- Lean meats and poultry
- Dairy or fortified alternatives
- Olive oil and other sources of unsaturated fat
This does not require rigid eating rules or the complete elimination of favorite foods. Instead, the limited appetite created by GLP-1 therapy should be treated as a nutritional budget. Protein, vegetables, fruit, fiber-rich carbohydrates, and healthy fats should receive priority before less nutrient-dense foods.
People with prolonged poor intake, highly restrictive diets, known deficiencies, anemia, osteoporosis risk, gastrointestinal disease, or previous bariatric surgery may require closer assessment by a physician and registered dietitian. Supplementation should be based on individual dietary intake, medical history, laboratory findings, and clinical need rather than assuming everyone requires the same products.
Hydration Must Become Intentional
Some individuals using GLP-1 medications consume less fluid because they feel full quickly, experience nausea, or simply lose the routine of drinking alongside regular meals. Vomiting or diarrhea can further increase fluid and electrolyte losses.
Adequate hydration supports:
- Normal bowel function
- Kidney function
- Blood-pressure regulation
- Temperature control
- Physical performance
- Delivery of nutrients throughout the body
More than 2 liters of fluid per day has been suggested in recent expert recommendations for many adults receiving GLP-1-based therapy, but needs vary according to body size, climate, exercise, pregnancy status, kidney or heart disease, and fluid losses. Patients with medical fluid restrictions should follow their clinician’s instructions.
Small, frequent sips may be better tolerated than drinking a large volume at once. Some people find it helpful to drink primarily between meals so that fluids do not worsen early fullness. Urine color, thirst, dizziness, dry mouth, constipation, and frequency of urination can provide useful but imperfect clues about hydration status.
Persistent vomiting, inability to retain fluids, markedly reduced urination, confusion, weakness, or symptoms of dehydration should be reported promptly to a healthcare professional.
Fiber: Essential, but Best Increased Gradually
Fiber remains critical during GLP-1 therapy because it supports bowel regularity, microbial diversity, glycemic control, cholesterol management, and long-term cardiometabolic health.
Fiber-rich foods include:
- Vegetables
- Berries, pears, apples, and other fruit
- Beans and lentils
- Oats and whole grains
- Chia seeds and ground flaxseed
- Nuts and seeds
Constipation is a common concern with GLP-1-based medications. However, rapidly adding a large amount of fiber when gastric emptying is already slowed may worsen bloating, pressure, or abdominal discomfort. Fiber should generally be increased progressively and accompanied by sufficient fluid. A mixture of soluble and insoluble fiber is beneficial. Soluble fiber, found in foods such as oats, beans, fruit, and psyllium, absorbs water and may support stool consistency. Insoluble fiber, present in many vegetables and whole grains, contributes bulk and supports intestinal transit.
The correct approach also depends on the symptom. Someone experiencing diarrhea may temporarily tolerate lower-fat, relatively bland foods better than a sudden increase in coarse fiber. Persistent or severe bowel changes should be evaluated rather than managed indefinitely through dietary experimentation.
Managing Gastrointestinal Side Effects Without Sacrificing Nutrition
Nausea, vomiting, diarrhea, and constipation are among the most frequently reported adverse effects of GLP-1-based medications. A 2025 systematic review and network meta-analysis of 39 studies involving 33,354 participants confirmed that these gastrointestinal effects occur across the medication class, although risk varies by medication and dose.
A multidisciplinary expert consensus recommends several practical strategies:
- Eat smaller meals
- Eat slowly and stop at the first signs of comfortable fullness
- Avoid lying down immediately after eating
- Limit large, high-fat meals, especially when nausea or reflux is present
- Avoid excessive alcohol
- Choose simpler, lower-fat foods during periods of nausea
- Maintain fluid intake through small, repeated servings
- Avoid increasing the dose faster than prescribed
- Contact the prescriber when symptoms are persistent or difficult to manage
These strategies should not become a permanently restrictive diet. Once symptoms improve, dietary variety should gradually return so that nutritional adequacy is restored. Severe or persistent abdominal pain, repeated vomiting, inability to remain hydrated, signs of gastrointestinal bleeding, jaundice, or symptoms that continue to worsen require medical evaluation.
Long-Term Dietary Quality Matters More Than a “GLP-1 Diet”
There is no single standardized GLP-1 diet. More importantly, people should not be encouraged to treat medication-related appetite suppression as a temporary crash diet. During the STEP 1 extension, participants regained an average of approximately two-thirds of their prior weight loss within one year after semaglutide and structured lifestyle support were withdrawn. This does not mean every patient will experience the same outcome, nor does it indicate that medication should necessarily be discontinued. It demonstrates that obesity is a chronic condition and that the biological pressures favoring weight regain can return. For some individuals, long-term pharmacotherapy may be appropriate. For others, treatment may change because of side effects, cost, access, pregnancy planning, medical considerations, or personal preference. In every situation, the dietary and behavioral skills developed during treatment remain important.
GLP-1 therapy may provide a period in which food cravings and intrusive thoughts about food are reduced. That period can be used to establish sustainable practices:
- Regular, balanced meals
- Consistent protein intake
- Greater dietary variety
- Routine hydration
- Gradually increased fiber
- Resistance and aerobic exercise
- Adequate sleep
- Strategies for stress and emotional eating
- Regular nutrition and medical follow-up
The objective is not to eat as little as possible. It is to build a dietary pattern capable of supporting muscle, bone, gastrointestinal health, cardiometabolic health, and quality of life over the long term.
The Future of GLP-1 Care Must Include Nutrition
GLP-1-based medications represent an important advance in obesity and diabetes care, but their success should not be measured by the scale alone. Weight loss that is accompanied by inadequate protein, poor hydration, micronutrient insufficiency, declining strength, or chronically poor dietary quality is not an optimal outcome.
The emerging evidence supports a more complete model of care: medication paired with individualized nutrition, physical activity, symptom management, nutritional monitoring, and behavioral support. The World Health Organization similarly emphasizes that GLP-1 therapies should form part of comprehensive, lifelong obesity care that includes a healthy diet, physical activity, and professional support. The GLP-1 era should therefore be viewed not as the end of nutrition-based care but as a reason to make that care more precise. When appetite becomes smaller, every bite matters more.
References
Christensen, S., Robinson, K., Thomas, S., & Williams, D. R. (2024). Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs. Obesity Pillars, 11, Article 100121. https://doi.org/10.1016/j.obpill.2024.100121
Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., Górriz, J. L., & Rubio-Herrera, M. Á. (2022). Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. Journal of clinical medicine, 12(1), 145. https://doi.org/10.3390/jcm12010145
Ismaiel, A., Scarlata, G. G. M., Boitos, I., Leucuta, D.-C., Popa, S.-L., Al Srouji, N., Abenavoli, L., & Dumitrascu, D. L. (2025). Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: A systematic review and network meta-analysis. International Journal of Obesity, 49, 1946–1957. https://doi.org/10.1038/s41366-025-01859-6
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., Gulati, M., Gupta, A., Horn, D., Kane, R. M., Saluja, J., Sannidhi, D., Stanford, F. C., & Callahan, E. A. (2025). Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity, 33(8), 1475–1503. https://doi.org/10.1002/oby.24336
Scott Butsch, W., Sulo, S., Chang, A. T., Kim, J. A., Kerr, K. W., Williams, D. R., Hegazi, R., Panchalingam, T., Goates, S., & Heymsfield, S. B. (2025). Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study. Obesity pillars, 15, 100186. https://doi.org/10.1016/j.obpill.2025.100186
Sievenpiper, J. L., Ard, J., Blüher, M., Chen, W., Dixon, J. B., Fitch, A., Gigliotti, L., Khunti, K., Lecube, A., Lean, M. E. J., Mittendorfer, B., Pfeiffer, A. F. H., Ryan, D. H., Vilsbøll, T., & Van Gaal, L. F. (2025). Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1–based therapies: An expert consensus statement using a modified Delphi approach. Obesity Pillars, 17, Article 100228. https://doi.org/10.1016/j.obpill.2025.100228
Wilding, J. P. H., Batterham, R. L., Calanna, S., Van Gaal, L. F., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. Journal of the Endocrine Society, 5(Suppl 1), A16–A17. https://doi.org/10.1210/jendso/bvab048.030
Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., Wadden, T. A., Wharton, S., Yokote, K., Kushner, R. F., & STEP 1 Study Group (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, obesity & metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725
World Health Organization. (2025, December 1). WHO issues global guideline on the use of GLP-1 medicines in treating obesity. https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity
